Morgan Stanley Downgrades Hologic on Challenging Near-term Upside

In a report published Monday, Morgan Stanley analyst David Lewis downgraded Hologic (NASDAQ: HOLX ) from Overweight to Equal-weight and removed their $22.00 price target. Although there is a balanced risk-reward following recent stock appreciation, Lewis noted that Morgan Stanley's “SOTP analysis suggests portfolio optimization may not be the quick